ARCUTIS BIOTHERAPEUTICS, INC. Interest Expense Nonoperating
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Interest Expense Nonoperating of $3.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $3.41M, a 12.45% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $4.37M, a 46.48% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $3.00M, a 45.94% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $3.07M, a 53.84% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $12.08M, a 55.52% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $27.17M, a 8.56% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $29.71M, a 89.83% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2022 was $15.65M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.41M 10-Q · filed 2026-08-05 | $7.77M 10-Q · filed 2026-08-05 | $10.78M derived: sum of 3 quarters · filed 2026-08-05 | $13.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.37M 10-Q · filed 2026-05-06 | $7.37M derived: sum of 2 quarters · filed 2026-05-06 | $10.44M derived: sum of 3 quarters · filed 2026-05-06 | $13.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.07M derived: sum of 2 quarters · filed 2026-02-25 | $9.10M derived: sum of 3 quarters · filed 2026-08-05 | $12.08M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.07M 10-Q · filed 2025-10-28 | $6.10M derived: sum of 2 quarters · filed 2026-08-05 | $9.08M 10-Q · filed 2025-10-28 | $14.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.03M 10-Q · filed 2026-08-05 | $6.01M 10-Q · filed 2026-08-05 | $11.56M derived: sum of 3 quarters · filed 2026-08-05 | $18.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.98M 10-Q · filed 2026-05-06 | $8.53M derived: sum of 2 quarters · filed 2026-05-06 | $15.19M derived: sum of 3 quarters · filed 2026-05-06 | $22.67M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.20M derived: sum of 2 quarters · filed 2026-02-25 | $19.69M derived: sum of 3 quarters · filed 2026-02-25 | $27.17M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.65M 10-Q · filed 2025-10-28 | $14.14M derived: sum of 2 quarters · filed 2025-10-28 | $21.62M 10-Q · filed 2025-10-28 | $29.38M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $7.48M 10-Q · filed 2025-08-06 | $14.96M 10-Q · filed 2025-08-06 | $22.73M derived: sum of 3 quarters · filed 2026-02-25 | $30.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $7.48M 10-Q · filed 2025-05-06 | $15.24M derived: sum of 2 quarters · filed 2026-02-25 | $22.80M derived: sum of 3 quarters · filed 2026-02-25 | $30.15M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.32M derived: sum of 2 quarters · filed 2026-02-25 | $22.67M derived: sum of 3 quarters · filed 2026-02-25 | $29.71M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.56M 10-Q · filed 2024-11-06 | $14.91M derived: sum of 2 quarters · filed 2024-11-06 | $21.95M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $7.35M 10-Q · filed 2024-08-14 | $14.39M 10-Q · filed 2024-08-14 | ||
| 2022-12-31 | $15.65M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |